Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites

Ponatinib, a pan-BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), causes severe side effects including vascular occlusions, pancreatitis, and liver toxicity, although the underlying mechanisms remain unclear. Modifications of critical proteins through reactive m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, De, Kostov, Rumen, Huang, Jeffrey T.-J., Henderson, Colin J., Wolf, C. Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2017
Materias:
Chemotherapy, Antibiotics, and Gene Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596814/
https://www.ncbi.nlm.nih.gov/pubmed/28882992
http://dx.doi.org/10.1124/jpet.117.243246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596814/
https://www.ncbi.nlm.nih.gov/pubmed/28882992
http://dx.doi.org/10.1124/jpet.117.243246

Ejemplares similares